Are Therapies That Target α-Synuclein Effective at Halting Parkinson’s Disease Progression? A Systematic Review
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241311022 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Abbie T Rodger und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby DE22 3DT, UK. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cultural Bureau and King Faisal University PhD Scholarship.
Abstract (Originalsprache)
There are currently no pharmacological treatments available that completely halt or reverse the progression of Parkinson’s Disease (PD). Hence, there is an unmet need for neuroprotective therapies. Lewy bodies are a neuropathological hallmark of PD and contain aggregated α-synuclein (α-syn) which is thought to be neurotoxic and therefore a suitable target for therapeutic interventions. To investigate this further, a systematic review was undertaken to evaluate whether anti-α-syn therapies are effective at preventing PD progression in preclinical in vivo models of PD and via current human clinical trials. An electronic literature search was performed using MEDLINE and EMBASE (Ovid), PubMed, the Web of Science Core Collection, and Cochrane databases to collate clinical evidence that investigated the targeting of α-syn. Novel preclinical anti-α-syn therapeutics provided a significant reduction of α-syn aggregations. Biochemical and immunohistochemical analysis of rodent brain tissue demonstrated that treatments reduced α-syn-associated pathology and rescued dopaminergic neuronal loss. Some of the clinical studies did not provide endpoints since they had not yet been completed or were terminated before completion. Completed clinical trials displayed significant tolerability and efficacy at reducing α-syn in patients with PD with minimal adverse effects. Collectively, this review highlights the capacity of anti-α-syn therapies to reduce the accumulation of α-syn in both preclinical and clinical trials. Hence, there is potential and optimism to target α-syn with further clinical trials to restrict dopaminergic neuronal loss and PD progression and/or provide prophylactic protection to avoid the onset of α-syn-induced PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby DE22 3DT, UK.
- Department of Biological Sciences, College of Science, King Faisal University, P.O. Box 400, Al-Ahsa 31982, Saudi Arabia.
ORCID-Profile: Maryam ALNasser, Wayne G Carter
Förderung
- Cultural Bureau and King Faisal University PhD Scholarship
Zitieren
APA
Rodger, A. T., ALNasser, M., & Carter, W. G. (2023). Are Therapies That Target α-Synuclein Effective at Halting Parkinson’s Disease Progression? A Systematic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241311022
Vancouver
Rodger AT, ALNasser M, Carter WG. Are Therapies That Target α-Synuclein Effective at Halting Parkinson’s Disease Progression? A Systematic Review. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241311022
BibTeX
@article{Rodger2023,
author = {Rodger, Abbie T and ALNasser, Maryam and Carter, Wayne G},
title = {Are Therapies That Target α-Synuclein Effective at Halting Parkinson’s Disease Progression? A Systematic Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241311022}
}
EUVIMED